Charley's Fund

Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia Mechelen, Belgium; 20 May 2010 – Galapagos NV (Euronext: GLPG) announced today that it has initiated a first-in-human trial for GLPG0492, its candidate drug for cachexia (loss of weight and muscle mass) and potentially other indications, such as Duchenne muscular dystrophy. GLPG0492 is an [...]

FOR IMMEDIATE RELEASE: CONTACT: January 9, 2008 Dr. Benjy Seckler Voice: (877) 436-3363 or (413) 528-5744 Email: info@charleysfund.org LOCAL MOM CHOSEN AS NATIONAL AWARD FINALIST BY COOKIE MAGAZINE Tracy Kramer Seckler, founder of Charley’s Fund, recognized for her outstanding contribution in seeking a cure for Duchenne Muscular Dystrophy South Egremont, MA, January 9, 2008 – [...]

Novel RNA-based therapeutic PRO051 to enter Phase I/II clinical trials in DMD Leiden, the Netherlands, December 27, 2007. Leiden University Medical Center (LUMC) and Biotech Company Prosensa announced today in the New England Journal of Medicine (van Deutekom et al.) positive results from the first ever clinical study with RNA-based therapeutic PRO051 in four patients [...]

CombinatoRx and Charley’s Fund/Nash Avery Foundation Collaborate to Develop Novel Agents for Duchenne Muscular Dystrophy $3 Million to Fund Drug Discovery and Product Development Program — Novel Mechanism Combination Pharmaceuticals to Treat Debilitating Muscle Wasting Disease with 100% Mortality Rate – CAMBRIDGE, Mass. & SOUTH EGREMONT, Mass.–(BUSINESS WIRE)–Nov. 8, 2007–CombinatoRx, Incorporated (NASDAQ: CRXX) today announced [...]

AVI BioPharma Receives Major Research and Development Grant From Charley’s Fund for Duchenne Muscular Dystrophy $2.45 Million Will Fund Research and Product Development Program PORTLAND, Ore., & SOUTH EGREMONT, Mass.–(BUSINESS WIRE)–AVI BioPharma, Inc. (Nasdaq:AVII), and Charley’s Fund, Inc., today announced that AVI has been awarded a $2.45 million research grant from Charley’s Fund, a nonprofit [...]